Apnimed's Cash & cash equivalent grew by 312.52 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Apnimed's Quick Ratio to 4.86 a new company high.

Within Major Pharmaceutical Preparations industry Apnimed, Inc. booked the highest Quick Ratio than Apnimed in the second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from to 920.

Explain Quick Ratio?
How much Cash & cash equivalents APMD�s has?
What are APMD�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/APMD/financial-strength

https://api.csimarket.com/api/v1/companies/APMD/fundamentals

https://api.csimarket.com/api/v1/companies/APMD/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

APMD Quick Ratio	(Jun 30 2026) Q2	(Dec 31 2025) Q2	Q2	Q2
Y / Y Current Liabilities Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	4.86	Subscribe	Subscribe	Subscribe	Subscribe
APMD's Total Ranking	# 920	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-70.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	312.52 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 0
Healthcare Sector	# 0
Overall Market	# 0

Quick Ratio Statistics
High	Average	Low
4.86	2.6	0.35
(Jun 30 2026)		(Dec 31 2025)

Financial Statements
Apnimed's Current Liabilities	$ 36 Millions	Visit APMD's Balance sheet
Apnimed's Cash & cash equivalent	$ 173 Millions	Visit APMD's Balance sheet
Source of APMD's Sales		Visit APMD's Sales by Geography

Cumulative Apnimed's Quick Ratio

APMD's Quick Ratio for the trailling 12 Months

APMD Quick Ratio	(Jun 30 2026) 12 Months	(Dec 31 2025) 12 Months	12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.37	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 920	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	29.41 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	412.52 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to APMD Financial Strength Comparisons >> Go to Compare APMD Quick Ratio to its Competitors

On the trailing twelve months basis APMD Cash & cash equivalent more than doubled by 312.52 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Apnimed's Quick Ratio to 1.37, Quick Ratio remained below APMD average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry APMD achieved the highest Quick Ratio. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents APMD�s has?
What are APMD�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 0
Healthcare Sector	# 0
Within the Market	# 920

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.86	2.6	0.35
(Jun 30 2026)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Aprea Therapeutics Inc	13.33	$ 41.233 Millions	$ 3.092 Millions
Polaryx Therapeutics Inc	13.22	$ 11.542 Millions	$ 0.873 Millions
Monopar Therapeutics Inc	13.14	$ 52.758 Millions	$ 4.016 Millions
Lexicon Pharmaceuticals Inc	12.96	$ 190.610 Millions	$ 14.706 Millions
Korro Bio Inc	12.89	$ 162.805 Millions	$ 12.628 Millions
Atea Pharmaceuticals Inc	12.89	$ 362.382 Millions	$ 28.124 Millions
Oric Pharmaceuticals Inc	12.76	$ 264.761 Millions	$ 20.756 Millions
Diamedica Therapeutics Inc	12.42	$ 81.875 Millions	$ 6.594 Millions
Vtv Therapeutics Inc	12.35	$ 86.643 Millions	$ 7.017 Millions
Theravance Biopharma inc	12.30	$ 378.546 Millions	$ 30.766 Millions
Coya Therapeutics Inc	12.29	$ 43.181 Millions	$ 3.512 Millions
Bridgebio Oncology Therapeutics Inc	12.28	$ 634.167 Millions	$ 51.634 Millions
Ocular Therapeutix Inc	12.17	$ 598.641 Millions	$ 49.174 Millions
Wave Life Sciences Ltd	12.07	$ 613.194 Millions	$ 50.815 Millions
Amylyx Pharmaceuticals Inc	11.86	$ 250.760 Millions	$ 21.150 Millions
Moonlake Immunotherapeutics	11.83	$ 537.000 Millions	$ 45.392 Millions
Eledon Pharmaceuticals Inc	11.77	$ 170.753 Millions	$ 14.503 Millions
Tyra Biosciences Inc	11.76	$ 354.060 Millions	$ 30.106 Millions
Opus Genetics Inc	11.69	$ 88.912 Millions	$ 7.605 Millions
Aardvark Therapeutics Inc	11.57	$ 73.921 Millions	$ 6.387 Millions
Dyne Therapeutics Inc	11.51	$ 898.475 Millions	$ 78.029 Millions
Evommune Inc	11.50	$ 201.014 Millions	$ 17.487 Millions
Bicara Therapeutics Inc	11.44	$ 497.259 Millions	$ 43.475 Millions
Lipocine Inc	11.25	$ 23.267 Millions	$ 2.068 Millions
Xenon Pharmaceuticals Inc	10.85	$ 930.686 Millions	$ 85.795 Millions
Bicycle Therapeutics Plc	10.71	$ 510.052 Millions	$ 47.635 Millions
Entrada Therapeutics Inc	10.44	$ 223.112 Millions	$ 21.371 Millions
Vera Therapeutics Inc	10.33	$ 499.161 Millions	$ 48.321 Millions
Ideaya Biosciences Inc	10.03	$ 828.955 Millions	$ 82.677 Millions
Gri Bio Inc	9.95	$ 10.947 Millions	$ 1.100 Millions

Date modified: 2026-10-19T03:48:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.